Actavis expands to Latin America

Friday, October 7, 2011 11:49 AM

Actavis Group CEO Claudio Albrecht has reported a major sales expansion into Latin America, among the world's fastest-growing markets for generic drugs.

Albrecht outlined the company's growth strategy with Actavis' new Latin American business unit. The Latin America team, based in Sunrise, Florida, will target Brazil, Argentina, Colombia, Mexico, Venezuela and other key markets in the region.  

With generic drugs not as widely used in South and Central America as in the United States and Europe, Albrecht said that Actavis' portfolio of nearly 900 lower-cost alternatives to brand medications represents a potential healthcare solution for millions. "This is not only a tremendous opportunity for Actavis to grow as a company, but also to bring great value to consumers while supporting better health," he said.

According to IMS Health, generic sales in Latin America grew by 14% from 2009 to 2010, compared to 4.4% worldwide. Generic sales in Latin America totaled $53.4 billion last year.

The Latin America unit, headed by Ricardo Quirch, also includes specialists in regulatory affairs, portfolio and business development, supply-chain management and business administration.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs